Mixolifuse Hero

Mixolifuse is formulated to support healthy levels of hair enzymes, which helps minoxidil work effectively to promote hair growth 1-4

Mixolifuse Logo

Hair Regrowth begins with healthy hair enzyme levels 2,3

Sulfotransferase is an important enzyme found in the scalp that is needed for healthy hair growth 2,3,5

Hair regrowth diagram
Hair regrowth chart
Hair regrowth chart

Hair regrowth chart

STA = sulfotransferase activity. *As measured by Optical Density (OD; 'Lower' ≤OD405<0.4, 'Higher' ≥ OD405>0.4), the conversion of minoxidil to minoxidil sulfate is coupled to the conversion of p-nitrophenyl sulfate to p-nitrophenyl, which can be quantified by optical absorbance at 405 nm

Adding Confidence

A hair growth routine you can feel confident about 1
Confidence chart
Hair regrowth chart

Hair regrowth chart
Adding Mixolifuse enriches hair enzymes...
Enzyme enhancement diagram
Hair regrowth chart

...enhancing Minoxidil's hair growth effect 1–3

Mixolifuse is a topical treatment specially formulated to enrich sulfotransferase activity 2-4

Easy to Use

Boost your chances of healthy hair regrowth by applying Mixolifuse 10 minutes before your daily Minoxidil hair treatment 1

Mixolifuse is a lightweight topical spray designed to easily integrate into a daily minoxidil hair growth routine1

Step 1
Step 2
Step 3
Hack Your Hair Growth
Step 4

Contact

Australian distributor for Mixolifuse is:
Glenmark Pharmaceuticals Australia Pty Limited
Suite 1503 Level 15, 14 Martin Place,
Sydney, NSW 2000, Australia.

For more information about Glenmark Pharmaceuticals, please visit: www.glenmark.com.au

Ready to buy Mixolifuse?
Contact your Pharmacy.

For Retail Pharmacists:
Interested to stock Mixolifuse?
Call Pharmabrokers on (02) 8878 9733

Local Contact:
Michael Moffitt, Country Manager
Australia & New Zealand
Telephone No.: (+61) 0412 387 087
Email: Michael.Moffitt@glenmarkpharma.com

Medical Information, Product Quality and Adverse Event Enquiries:
Telephone No.: 1800 371 274
Email: Medinfo.Australia@glenmarkpharma.com

References: 1. Dhurat R et al. J Cosmet Dermatol 2022;21(1):343–346. 2. Pietrauszka K, Bergler-Czop B. Adv Dermatol Allergol 2022;39(3):472–478. 3. Ramos PM et al. J Eur Acad Dermatol Venereol 2020;34(12):e799–e800. 4. Goren A et al. Dermatol Ther 2014;27(3):171–3. 5. Cortez GL et al. An Bras Dermatol 2025;100(2):308–321.

GLE0020; Date of preparation: November 2025. G-INPLMS32360.